Direction at a glance
Broadly neutralizing antibodies can directly block susceptible HIV variants and recruit immune functions. Combinations are designed to widen coverage and reduce escape, with studies testing prevention, treatment support and remission after pausing ART.
What the evidence establishes
- Single antibodies are vulnerable to pre-existing resistance and viral escape.
- Triple-antibody clinical research has evaluated safety and antiviral activity.
- Combination immunotherapy studies have identified immune and virologic correlates associated with delayed rebound in some participants.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
Delayed rebound is not eradication, and responses vary substantially. Analytical treatment interruption requires intensive monitoring and cannot be inferred from laboratory markers alone.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodiesNature Medicine · Primary research · Access checked 18 Aug 2026
↗02Correlates of HIV-1 control after combination immunotherapyNature · Primary research · Access checked 18 Aug 2026
↗03ClinicalTrials.gov HIV study registryU.S. National Library of Medicine · Registry · Access checked 18 Aug 2026
↗